Skip to main content
Premium Trial:

Request an Annual Quote

CIDR Using Affy's SNP Array 6.0 for Inherited Disease Studies Services

NEW YORK (GenomeWeb News) – The Center for Inherited Disease Research is using Affymetrix’ Genome-Wide Human SNP Array 6.0 for large-scale genotyping and copy number projects conducted for researchers working through the National Institutes of Health, Affymetrix said today.
The federally funded CIDR is based at Johns Hopkins University and focuses on offering genotyping and statistical genetics services to scientists who are trying to identify genes that could contribute to human multifactorial hereditary diseases.
The first such project using the Affymetrix technology is a study of the genetic causes of type 2 diabetes in African Americans and is funded through the National Institute of Diabetes and Digestive and Kidney Diseases, the company said.
Affy said its genome-wide mapping arrays have been used recently in similar studies of type 2 diabetes in Nordic and Parsi populations.
Financial terms of the agreement were not released.
More information about CIDR’s services, which are available to all investigators through competitive peer review, may be found at the center’s website.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.